biotechexpert: By your name I assume you know more
Post# of 30028
Posted On: 08/30/2014 12:00:03 AM
Re: biotechexpert #4999
biotechexpert: By your name I assume you know more about biotech than I do.
But you know.... Gerald presented some data on the univariant biomarkers for LymPro in July that were awesome! Did you know we have 5 univariant biomarkers? When you measure them individually, their numbers are only in the 70s and 80s. But when you combine them all (multivariant) that is when the numbers get into the 90s. We'll be getting those multivariant numbers soon enough. But the scientists attending those Conferences in July did understand what he was presenting and were duly impressed. It was only the uneducated shareholders that did not understand the data and sold off as a result.
Did you know that our competitor Amivid, from Eli Lilly, can only test for one univariant biomarker? They do OK when testing healthy people against those with Alzheimers because their test can identify plaque. But did you know that amivid has a real hard time distinguishing alzheimers from other forms of dementia? That is a real problem for Big Pharma doing clinical trials. They need to know who actually has alzheimers, rather than dementia! That is critical. And that is what LymPro does better than any other test on the market today! Those 5 univariant biomarkers gives us an edge.
Back in July the data was good that was presented! But it will be even better this next week when we get the complete data. And, maybe Gerald was incentivized to delay the results until he could get the numbers up higher?Perhaps the amount of cash we get from our partner is linked to the data results? Gerald has been holding out until the last moment to get us the most money from our partner. His tweet today wouldn't have happened if the partnership had fallen apart.
I'm thinking Gerald is doing fine for us and is about to make me rich! I'm thinking about naming our next son "Gerald!" We're both 55 now, so that's not going to happen, but you get the point.
But you know.... Gerald presented some data on the univariant biomarkers for LymPro in July that were awesome! Did you know we have 5 univariant biomarkers? When you measure them individually, their numbers are only in the 70s and 80s. But when you combine them all (multivariant) that is when the numbers get into the 90s. We'll be getting those multivariant numbers soon enough. But the scientists attending those Conferences in July did understand what he was presenting and were duly impressed. It was only the uneducated shareholders that did not understand the data and sold off as a result.
Did you know that our competitor Amivid, from Eli Lilly, can only test for one univariant biomarker? They do OK when testing healthy people against those with Alzheimers because their test can identify plaque. But did you know that amivid has a real hard time distinguishing alzheimers from other forms of dementia? That is a real problem for Big Pharma doing clinical trials. They need to know who actually has alzheimers, rather than dementia! That is critical. And that is what LymPro does better than any other test on the market today! Those 5 univariant biomarkers gives us an edge.
Back in July the data was good that was presented! But it will be even better this next week when we get the complete data. And, maybe Gerald was incentivized to delay the results until he could get the numbers up higher?Perhaps the amount of cash we get from our partner is linked to the data results? Gerald has been holding out until the last moment to get us the most money from our partner. His tweet today wouldn't have happened if the partnership had fallen apart.
I'm thinking Gerald is doing fine for us and is about to make me rich! I'm thinking about naming our next son "Gerald!" We're both 55 now, so that's not going to happen, but you get the point.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼